Basic Information
| LncRNA/CircRNA Name | MALAT1 |
| Synonyms | NA |
| Region | GRCh38_11:65497688-65506516 |
| Ensemble | ENSG00000251562 |
| Refseq | NR_002819 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | PI3K inhibitor LY294002 | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cutaneous squamous cell carcinoma |
| ICD-0-3 | C49 |
| Methods | qPCR, Western blot, in vitro knockdown, RNAi, RIP, etc. |
| Sample | cSCC primary tumors tissues, cSCC lines A431, HSC-1, and HSC-5 , the human benign epidermal keratinocyte cell line HaCaT, cervical cancer cell line Hela and melanoma cell line A375 |
| Expression Pattern | up-regulated |
| Function Description | functional studies using in vitro cellular and in vivo xenograft models confirmed the pro-carcinogenic roles of MALAT1 in cSCC. Further, MALAT1 was identified to regulate epidermal growth factor receptor (EGFR) protein expression but did not affect EGFR mRNA expression. Transcriptomic sequencing identified kinectin 1 (KTN1) as the key mediator for MALAT1 regulation of EGFR. Mechanistic study revealed that MALAT1 interacts with c-MYC to form a complex and directly binds to the promoter region of KTN1 gene and enhances its transactivation to positively regulate EGFR protein expression. Our findings, therefore, establish a novel c-MYC-assisted MALAT1-KTN1-EGFR axis, which contributes to cSCC development and may serve as novel target for therapeutic intervention |
| Pubmed ID | 30683916 |
| Year | 2019 |
| Title | MALAT1-KTN1-EGFR regulatory axis promotes the development of cutaneous squamous cell carcinoma |
External Links
| Links for MALAT1 | GenBank HGNC NONCODE |
| Links for cutaneous squamous cell carcinoma | OMIM COSMIC |